Management of failed flow diversion for intracranial aneurysm beyond the first 6 months of follow-up: an international Delphi consensus.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chintapalli Renuka, Nguyen Sarah, Taussky Philipp, Grandhi Ramesh, Dammann Philipp, Raygor Kunal, Tonetti Daniel A, Andersson Tommy, White Philip, Ogilvy Christopher S, Chapot Rene, Fox W Christopher, Tawk Rabih G, Lanzino Giuseppe, Hanel Ricardo, Jadhav Ashutosh, Hassan Ameer E, Linfante Italo, Almefty Rami, Mascitelli Justin, Fargen Kyle, Levitt Michael R, Burkhardt Jan-Karl, Jankowitz Brian T, Jabbour Pascal, Starke Robert M, Gross Bradley A, Kan Peter, Killer-Oberpfalzer Monika, Rautio Riitta, Dmytriw Adam A, Coulthard Alan, Dabus Guilherme, Raper Daniel, Deuschl Cornelius, Kilburg Craig, Budohoski Karol P, Abla Adib A
Аннотация
METHODS: An international panel of 67 experts was invited to participate in a multistep Delphi consensus process on the treatment of intracranial aneurysms after failed flow diversion.
RESULTS: Of the 67 experts invited, 23 (34%) participated. Qualitative analysis of an initial survey with open-ended questions resulted in 51 statements regarding management of aneurysms showing persistent filling after flow diversion. The statements were grouped into 8 categories, and in the second round, respondents rated the degree of their agreement with each statement on a 5-point Likert scale. Flow diverters with surface modifiers did not influence administration of dual-antiplatelet therapy according to 83%. Consensus was also reached regarding the definition of treatment failure at specific time points, including at 6 months if there is aneurysm growth or persistent rapid flow through the entirety of the aneurysm (96%), at 12 months if there is aneurysm growth or symptom onset (78%), and at 24 months if there is persistent filling regardless of size and filling characteristics (74%). Although experts agreed that the degree of intimal hyperplasia or in-device stenosis could not be ascertained by noninvasive imaging alone (83%), only 65% chose digital subtraction angiography as the preferred modality. At 6 and 12 months, retreatment is preferred if there is persistent filling with aneurysm growth (96%, 96%), device malposition (48%, 87%), or a history of subarachnoid hemorrhage (65%, 70%), respectively, and at 24 months if there is persistent filling without reduction in aneurysm size (74%). Experts favored treatment with an additional flow diverter (87%) over aneurysm clipping, applying the same principles for follow-up (83%) and treatment failure (91%) as for the first flow diverter.
CONCLUSIONS: The authors present the consensus practices of experts in the management of intracranial aneurysms without occlusion 6-24 months after treatment with a flow-diverting device.